Combinations of Eszopiclone and an Antidepressant
    3.
    发明申请
    Combinations of Eszopiclone and an Antidepressant 审中-公开
    依曲普洛酮和抗抑郁药的组合

    公开(公告)号:US20090111817A1

    公开(公告)日:2009-04-30

    申请号:US11994647

    申请日:2006-07-05

    IPC分类号: A61K31/4985

    摘要: One aspect of the present invention relates to pharmaceutical compositions containing two or more active agents that when taken together can be used to treat, e.g., menopause, mood disorders, anxiety disorders, or cognitive disorders. The first component of the pharmaceutical composition is a sedative eszopiclone. The second component of the pharmaceutical composition is an antidepressant. The present invention also relates to a method of treating menopause, perimenopause, mood disorders, anxiety disorders, and cognitive disorders.

    摘要翻译: 本发明的一个方面涉及含有两种或更多种活性剂的药物组合物,所述活性剂当一起用于治疗例如更年期,情绪障碍,焦虑障碍或认知障碍时。 药物组合物的第一组分是镇静剂佐佐匹克。 药物组合物的第二组分是抗抑郁药。 本发明还涉及治疗绝经,围绝经期,情绪障碍,焦虑障碍和认知障碍的方法。

    Combinations of Eszopiclone and O-Desmethylvenlafaxine, and Methods of Treatment of Menopause and Mood, Anxiety, and Cognitive Disorders
    4.
    发明申请
    Combinations of Eszopiclone and O-Desmethylvenlafaxine, and Methods of Treatment of Menopause and Mood, Anxiety, and Cognitive Disorders 审中-公开
    依曲替康和O-去甲基文拉法辛的组合以及更年期和心理,焦虑和认知障碍的治疗方法

    公开(公告)号:US20090111818A1

    公开(公告)日:2009-04-30

    申请号:US11994638

    申请日:2006-07-05

    IPC分类号: A61K31/4985

    摘要: One aspect of the present invention relates to pharmaceutical compositions containing two or more active agents that when taken together can be used to treat, e.g., menopause, mood disorders, anxiety disorders, or cognitive disorders. The first component of the pharmaceutical composition is a sedative eszopiclone. The second component of the pharmaceutical composition is O-desmethylvenlafaxine. The present invention also relates to a method of treating menopause, perimenopause, mood disorders, anxiety disorders, and cognitive disorders.

    摘要翻译: 本发明的一个方面涉及含有两种或更多种活性剂的药物组合物,所述活性剂当一起用于治疗例如更年期,情绪障碍,焦虑障碍或认知障碍时。 药物组合物的第一组分是镇静剂佐佐匹克。 药物组合物的第二组分是O-去甲基文拉法辛。 本发明还涉及治疗绝经,围绝经期,情绪障碍,焦虑障碍和认知障碍的方法。

    Methods of modulating processes mediated by excitatory amino acid receptors
    9.
    发明授权
    Methods of modulating processes mediated by excitatory amino acid receptors 失效
    调节由兴奋性氨基酸受体介导的过程的方法

    公开(公告)号:US06956049B1

    公开(公告)日:2005-10-18

    申请号:US09387135

    申请日:1999-08-31

    CPC分类号: C07D277/22 A61K31/425

    摘要: In accordance with the present invention, there are provided methods of modulating the activity of excitatory amino acid receptors using a specifically defined class of heterocyclic compounds. In one embodiment, there are provided methods of modulating metabotropic glutamate receptors. The present invention also discloses methods of treating disease using heterocyclic compounds. Diseases contemplated include cerebral ischemia, chronic neurodegeneration, psychiatric disorders, schizophrenia, mood disorders, emotion disorders, disorders of extrapyramidal motor function, obesity, disorders of respiration, motor control and function, attention deficit disorders, concentration disorders, pain disorders, neurodegenerative disorders, epilepsy, convulsive disorders, eating disorders, sleep disorders, sexual disorders, circadian disorders, drug withdrawal, drug addiction, compulsive disorders, anxiety, panic disorders, depressive disorders, skin disorders, retinal ischemia, retinal degeneration, glaucoma, disorders associated with organ transplantation, asthma, ischemia and astrocytomas. The invention further discloses methods of preventing disease conditions related to diseases of the pulmonary system, diseases of the nervous system, diseases of the cardiovascular system, diseases of the gastrointestinal system, diseases of the endocrine system, diseases of the exocrine system, diseases of the skin, cancer and diseases of the ophthalmic system. The invention also discloses pharmaceutically acceptable salt forms of heterocyclic compounds.

    摘要翻译: 根据本发明,提供了使用特定限定类杂环化合物调节兴奋性氨基酸受体活性的方法。 在一个实施方案中,提供了调节代谢型谷氨酸受体的方法。 本发明还公开了使用杂环化合物治疗疾病的方法。 预期的疾病包括脑缺血,慢性神经变性,精神疾病,精神分裂症,情绪障碍,情绪障碍,锥体外系运动功能障碍,肥胖症,呼吸障碍,运动控制和功能,注意力缺陷障碍,集中症,疼痛障碍,神经变性疾病, 癫痫症,惊厥性疾病,进食障碍,睡眠障碍,性障碍,昼夜节律障碍,药物戒断,药物成瘾,强迫症,焦虑症,恐慌症,抑郁症,皮肤病症,视网膜缺血,视网膜变性,青光眼,器官移植相关疾病 ,哮喘,局部缺血和星形细胞瘤。 本发明还公开了预防与肺系统疾病,神经系统疾病,心血管系统疾病,胃肠系统疾病,内分泌系统疾病,外分泌系统疾病, 皮肤,癌症和眼科疾病。 本发明还公开了药学上可接受的杂环化合物的盐形式。